The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities

Forensic Toxicology

Volumn 34, Issue 2, 2016, Pages 286-303

  Longworth, Mitchell ^a   Banister, Samuel D ^a,b   Mack, James B C ^c   Glass, Michelle ^d   Connor, Mark ^e   Kassiou, Michael ^a,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e MACQUARIE UNIVERSITY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

2H indazole regioisomer; CHMINACA; FUBINACA; Indazole synthetic cannabinoid; Manufacturing impurity with cannabinoid activity; PINACA

Indexed keywords

EID: 84964462208     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-016-0316-y     Document Type: Article

References (59)

1. Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587–597
2. Auwärter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837
3. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66
4. European Monitoring Centre for Drugs and Drug Addiction (2015) EMCDDA–Europol 2014 annual report on the implementation of council decision 2005/387/JHA, implementation reports. Publications Office of the European Union, Luxembourg. doi:10.2810/112317. Accessed 1 Feb 1, 2016
5. Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2014) Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test Anal 6:832–839
6. Zawilska JB, Andrzejczak D (2015) Next generation of novel psychoactive substances on the horizon—a complex problem to face. Drug Alcohol Depend 157:1–17
7. Blakey K, Boyd S, Atkinson S, Wolf J, Slottje PM, Goodchild K, McGowan J (2015) Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense. Forensic Sci Int 260:40–53
8. Kondrasenko AA, Goncharov EV, Dugaev KP, Rubaylo AI (2015) CBL-2201. Report on a new designer drug: naphth-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate. Forensic Sci Int 257:209–213
9. McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O’Brien J, Talbot B, Dowling G, Brandt SD (2015) The synthesis and characterization of the ‘research chemical’ N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer. Drug Test Anal. doi:10.1002/dta.1864
10. Uchiyama N, Asakawa K, Kikura-Hanajiri R, Tsutsumi T, Hakamatsuka T (2015) A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] identified in illegal products. Forensic Toxicol 33:367–373
11. Westphal F, Sönnichsen FD, Knecht S, Auwärter V, Huppertz L (2015) Two thiazolylindoles and a benzimidazole: novel compounds on the designer drug market with potential cannabinoid receptor activity. Forensic Sci Int 249:133–147
12. Qian Z, Hua Z, Liu C, Jia W (2016) Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances. Forensic Toxicol 34:133–143
13. Shevyrin V, Melkozerov V, Eltsov O, Shafran Y, Morzherin Y (2016) Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances. Forensic Sci Int 259:95–100
14. Lobo Vicente J, Chassaigne H, Holland MV, Reniero F, Kolar K, Tirendi S, Vandecasteele I, Vinckier I, Guillou C (2016) Systematic analytical characterization of new psychoactive substances: a case study. Forensic Sci Int 265:107–115
15. Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009) Indazole derivatives as CB1 receptor modulators and their preparation and use in treatment of diseases. Patent WO 2009/106980
16. Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009) Indazole derivatives as CB1 receptor modulators and their preparation and use in the treatment of CB1-mediated diseases. Patent WO 2009/106982
17. Centers for Disease Control and Prevention (2013) Notes from the field: severe illness associated with synthetic cannabinoid use-Brunswick, Georgia, 2013. Morb Mortal Wkly Rep 62:939
18. Centers for Disease Control and Prevention (2013) Notes from the field: severe illness associated with reported use of synthetic marijuana-Colorado, August–September 2013. Morb Mortal Wkly Rep 62:1016–1017
19. Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O (2014) Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms. Forensic Toxicol 33:45–53
20. Monte AA, Bronstein AC, Cao DJ, Heard KJ, Hoppe JA, Hoyte CO, Iwanicki JL, Lavonas EJ (2014) An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med 370:389–390
21. Hess C, Stockhausen S, Kernbach-Wighton G, Madea B (2015) Death due to diabetic ketoacidosis: induction by the consumption of synthetic cannabinoids? Forensic Sci Int 257:e6–e11
22. Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR (2015) A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 48:573–580
23. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (2015) Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group. Anal Bioanal Chem 407:6301–6315
24. Labay LM, Caruso JL, Gilson TP, Phipps RJ, Knight LD, Lemos NP, McIntyre IM, Stoppacher R, Tormos LM, Wiens AL, Williams E, Logan BK (2016) Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int 260:31–39
25. Shanks KG, Clark W, Behonick G (2016) Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol. doi:10.1093/jat/bkv142
26. Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T (2014) Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol 32:266–281
27. Langer N, Lindigkeit R, Schiebel H-M, Papke U, Ernst L, Beuerle T (2015) Identification and quantification of synthetic cannabinoids in “spice-like” herbal mixtures: update of the German situation for the spring of 2015. Forensic Toxicol 34:94–107
28. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 31:93–100
29. European Monitoring Centre for Drugs and Drug Addiction (2014) EMCDDA–Europol 2013 annual report on the implementation of council decision 2005/387/JHA, implementation reports. Publications Office of the European Union, Luxembourg. doi:10.2810/51986. Accessed 1 Feb 2016
30. Wilkinson SM, Banister SD, Kassiou M (2015) Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust J Chem 68:4–8
31. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M (2015) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 6:1546–1559
32. 9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther 354:328–339
33. 9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav Pharmacol 26:460–468
34. Thornton SL, Akpunonu P, Glauner K, Hoehn KS, Gerona R (2015) Unintentional pediatric exposure to a synthetic cannabinoid (AB-PINACA) resulting in coma and intubation. Ann Emerg Med 66:343–344
35. Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373:103–107
36. Tyndall JA, Gerona R, De Portu G, Trecki J, Elie MC, Lucas J, Slish J, Rand K, Bazydlo L, Holder M, Ryan MF, Myers P, Iovine N, Plourde M, Weeks E, Hanley JR, Endres G, St Germaine D, Dobrowolski PJ, Schwartz M (2015) An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol 53:950–956
37. Drug Enforcement Administration, Department of Justice (2014) Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. Fed Regist 79:7577–7582
38. Drug Enforcement Administration, Department of Justice (2015) Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order. Fed Regist 80:5042–5047
39. Erratico C, Negreira N, Norouzizadeh H, Covaci A, Neels H, Maudens K, van Nuijs AL (2015) In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA. Drug Test Anal 7:866–876
40. Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K (2016) Identification and quantification of metabolites of AB-CHMINACA in a urine specimen of an abuser. Leg Med 19:113–118
41. Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, Goda Y, Toyo’oka T (2014) UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome. Biomed Chromatogr 28:831–838
42. Castaneto MS, Wohlfarth A, Pang S, Zhu M, Scheidweiler KB, Kronstrand R, Huestis MA (2015) Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. Forensic Toxicol 33:295–310
43. Vikingsson S, Green H, Brinkhagen L, Mukhtar S, Josefsson M (2015) Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. Drug Test Anal. doi:10.1002/dta.1896
44. Hsin-Hung Chen M, Dip A, Ahmed M, Tan ML, Walterscheid JP, Sun H, Teng BB, Mozayani A (2016) Detection and characterization of the effect of AB-FUBINACA and its metabolites in a rat model. J Cell Biochem 117:1033–1043
45. Jang M, Shin I, Kim J, Yang W (2015) Simultaneous quantification of 37 synthetic cannabinoid metabolites in human urine by liquid chromatography-tandem mass spectrometry. Forensic Toxicol 33:221–234
46. Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA (2015) Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J 17:660–677
47. Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M (2015) Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol 33:175–194
48. DeRuiter J, Smith FT, Abdel-Hay K, Clark CR (2014) Analytical differentiation of 1-alkyl-3-acylindoles and 1-acyl-3-alkylindoles: isomeric synthetic cannabinoids. Anal Chem 86:3801–3808
49. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y (2014) 3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures. Forensic Sci Int 242:72–80
50. Girreser U, Rosner P, Vasilev A (2015) Structure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted C NMR shifts—a case study. Drug Test Anal. doi:10.1002/dta.1820
51. Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T (2015) A synthetic cannabinoid FDU-NNEI, two 2-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N-OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products. Forensic Toxicol 33:244–259
52. Jia W, Meng X, Qian Z, Hua Z, Li T, Liu C (2016) Identification of three cannabimimetic indazole and pyrazole derivatives, APINACA 2H-indazole analogue, AMPPPCA, and 5F-AMPPPCA. Drug Test Anal. doi:10.1002/dta.1967
53. Choi H, Heo S, Choe S, Yang W, Park Y, Kim E, Chung H, Lee J (2013) Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Anal Bioanal Chem 405:3937–3944
54. Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2013) The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci 4:1081–1092
55. Knapman A, Santiago M, Du YP, Bennallack PR, Christie MJ, Connor M (2013) A continuous, fluorescence-based assay of µ-opioid receptor activation in AtT-20 cells. J Biomol Screen 18:269–276
56. Yet L (2009) Chapter 5.4: five-membered ring systems: with more than one N atom. In: Gordon WG, John AJ (eds) Progress in heterocyclic chemistry, vol 20. Elsevier, Amsterdam, pp 190–219
57. Hunt KW, Moreno DA, Suiter N, Clark CT, Kim G (2009) Selective synthesis of 1-functionalized-alkyl-1H-indazoles. Org Lett 11:5054–5057
58. Saenz J, Mitchell M, Bahmanyar S, Stankovic N, Perry M, Craig-Woods B, Kline B, Yu S, Albizati K (2007) Process development and scale-up of AG035029. Org Process Res Dev 11:30–38
59. Grimsey NL, Graham ES, Dragunow M, Glass M (2010) Cannabinoid receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. Biochem Pharmacol 80:1050–1062